EVKIF Stock Chart & Stats
$20.80
--
Market closed
$20.80
--
Day’s Range― - ―
52-Week Range$14.49 - $23.56
Previous CloseN/A
VolumeN/A
Average Volume (3M)329.00
Market Cap
$8.44B
Enterprise Value$10.92B
Total Cash (Recent Filing)$589.00M
Total Debt (Recent Filing)$4.16B
Price to Earnings (P/E)46.9
Beta0.51
Next Earnings
Aug 04, 2026EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend Yield9.18%
Share Statistics
EPS (TTM)0.34
Shares Outstanding466,000,000
10 Day Avg. Volume50
30 Day Avg. Volume329
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)0.77
Price to Sales (P/S)0.44
P/FCF Ratio8.96
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit3.52
Enterprise Value/Ebitda6.20
Forecast
1Y Price Target
$19.77Price Target Upside-4.93% Downside
Rating ConsensusHold
Number of Analyst Covering11
EPS Forecast (FY)1.72
Revenue Forecast (FY)$16.53B
Bulls Say, Bears Say
Bulls Say
Specialty, Diversified Business ModelEvonik's focus on specialty chemicals and multiple end markets (additives, performance materials, nutrition & care) supports durable demand diversification and pricing via differentiated products and technical application support. Recurring supply relationships and application know-how underpin long-term resilience and margin support versus commodity peers.
Solid Operating Cash Flow And Positive FCFConsistent positive operating cash flow and meaningful free cash flow provide the company with the ability to fund capex, R&D and dividends without forced financing. Reliable cash generation underpins strategic flexibility and capacity to invest in higher-margin specialty segments over the medium term.
Moderate Leverage, Balance-sheet FlexibilityA debt-to-equity ratio near 0.48 indicates conservative-to-moderate leverage for a chemicals business, leaving room to absorb cyclical shocks, pursue selective acquisitions, or increase strategic reinvestment. This balance-sheet headroom supports long-term capital allocation without excessive refinancing risk.
Bears Say
Multi-year Revenue DeclineA sustained top-line downtrend reduces operating leverage and limits the firm's ability to rebuild margins via scale. If underlying end-market demand or volume mix does not recover, the business may face persistent pressure on utilization, pricing leverage and long-term growth prospects.
Thin Net Margins And Low ROEVery slim net margins and weak ROE signal limited profitability after below-the-line costs (depreciation, interest). Over time, low earnings power constrains reinvestment, dividends and valuation room; lifting ROE will require sustained margin improvement or higher-value product mix shifts.
Softening Free Cash Flow And Cash ConversionDeclining FCF and subpar cash conversion reduce internal funding for growth and increase reliance on operational improvements to finance strategic initiatives. Persistent softening may force prioritization between capex, R&D and shareholder returns, limiting long-term investment in higher-margin segments.
Evonik News
EVKIF FAQ
What was Evonik’s price range in the past 12 months?
Evonik lowest stock price was $14.49 and its highest was $23.56 in the past 12 months.
What is Evonik’s market cap?
Evonik’s market cap is $8.44B.
When is Evonik’s upcoming earnings report date?
Evonik’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Evonik’s earnings last quarter?
Evonik released its earnings results on May 08, 2026. The company reported $0.388 earnings per share for the quarter, beating the consensus estimate of $0.348 by $0.04.
Is Evonik overvalued?
According to Wall Street analysts Evonik’s price is currently Overvalued.
Does Evonik pay dividends?
Evonik pays a Annually dividend of $1.153 which represents an annual dividend yield of 9.18%. See more information on Evonik dividends here
What is Evonik’s EPS estimate?
Evonik’s EPS estimate is 0.59.
How many shares outstanding does Evonik have?
Evonik has 466,000,000 shares outstanding.
What happened to Evonik’s price movement after its last earnings report?
Evonik reported an EPS of $0.388 in its last earnings report, beating expectations of $0.348. Following the earnings report the stock price went up 2.535%.
Which hedge fund is a major shareholder of Evonik?
Currently, no hedge funds are holding shares in EVKIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evonik Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$19.77 (-4.93% Downside)
$19.77 (-4.93% Downside)
Blogger Sentiment
Bullish
EVKIF Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $600.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.74%
12-Months-Change
Fundamentals
Return on Equity
1.89%
Trailing 12-Months
Asset Growth
-8.82%
Trailing 12-Months
Company Description
Evonik
Evonik Industries AG operates primarily in the specialized chemicals market. Its business activities are structured across five principal divisions: Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure. The Specialty Additives segment is responsible for delivering essential ingredients such as polyurethane additives, modified silicones, isophorones, epoxy hardeners, oil modifiers, fumed silicas, matting agents, TAA compounds, and acetylenic diol-based surfactants, which find use in consumer products and various industrial applications. In the Nutrition & Care division, Evonik provides compounds like amphoteric surfactants, ceramides, phytosphingosines, oleochemicals, quaternary derivatives, amino acids and their derivatives, synthetic products, pharmaceutical-grade polymers, and DL-methionine. These are crucial for consumer goods, animal nutrition, and healthcare industries. The Smart Materials segment manufactures advanced substances including hydrogen peroxide, peracetic acid, various activated nickel and precious metal catalysts (for powder, oil, and fat hydrogenation), amorphous polyalphaolefins, polybutadienes, polyester resins, thermoplastic and reactive methacrylate resins, PEEK, polyamide 12, organosilanes, chlorosilanes, and different types of silicas (fumed and precipitated). These serve a broad spectrum of industries including automotive, paints, coatings, adhesives, and construction. Through its Performance Materials segment, the company produces polymer materials and intermediate chemicals, including butene-1, DINP, isononanol, cyanuric chloride, alkoxides, and superabsorbents, specifically for the rubber, plastics, and automotive sectors. Lastly, the Technology & Infrastructure segment provides crucial internal services, encompassing site management, utilities and waste disposal, technical expertise, process technology, engineering, and logistics. Evonik maintains a significant international presence, with operations spanning across the Asia-Pacific region, Europe, the Middle East, Africa, Central and South America, and North America. Founded in 1873, the firm's main offices are located in Essen, Germany, and it functions as a subsidiary of RAG-Stiftung.
EVKIF Stock 12 Month Forecast
Average Price Target
$19.77
▼(-4.93% Downside)
Ownership Overview
― Insiders
7.81% Mutual Funds
<0.01% Other Institutional Investors
82.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---